May 10, 2021 10:28 AM EDTUpdated 02:16 PM
R&D

Bay­er claims an­oth­er win on its CKD and di­a­betes hope­ful, though the ques­tion re­mains over just how big it is

Max Gelman

Senior Editor

Af­ter earn­ing pri­or­i­ty re­view for a top CKD and di­a­betes pro­gram back in Jan­u­ary, Bay­er is re­veal­ing more da­ta that it hopes will boost …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

As­traZeneca, Dai­ichi’s TROP2 drug miss­es over­all sur­vival goal in Phase 3 breast can­cer tri­al

UK vac­cine start­up Vice­bio snags $100M to take on GSK, Pfiz­er and Mod­er­na

Ideaya out­lines reg­u­la­to­ry path for rare eye can­cer drug af­ter pos­i­tive mid-stage da­ta

Reg­u­la­to­ry RNA start­up CAMP4 files for IPO as more biotechs line up list­ings

A VC-backed ge­net­ic test­ing start­up to 'con­sid­er' mak­ing an of­fer to buy 23andMe

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times